Critical event management provider OnSolve stated on Wednesday that the public health authorities are using its CodeRED product to communicate with citizens and first responders regarding the COVID-19 vaccine availability and immunization logistics across the US.
The company has established a public advisory to help government officials at the local, state and federal levels, as well healthcare organizations, including hospitals, maximize their efforts to effectively and safely organize their COVID-19 vaccination effort.
Currently, nearly 200 communities are using the company's CodeRed to manage the sharing of information related to COVID-19 vaccine deployment and nearly 640,000 messages related to vaccine deployment have been sent. They are leveraging CodeRED's rapid, tailored critical communications capabilities and easy integration with other emergency management solutions for this vital public health project.
In conjunction, Coles County Health Department in Charleston, Illinois will use the company's CodeRED emergency notification solution to communicate critical information related to COVID-19 vaccine deployment in the area.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results